ALLISON BROWN: Open Payments
NPI 1063978336 · HUNTSVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,330 in 53 payments from 16 companies in 2025. Trend: 2023 $595 · 2024 $826 · 2025 $1,330
Food & beverage: $1,330
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 15 | $414 |
| Ardelyx, Inc. | 3 | $162 |
| Vifor Pharma, Inc. | 6 | $142 |
| Calliditas Therapeutics US Inc. | 4 | $99 |
| Otsuka America Pharmaceutical, Inc. | 5 | $94 |
| OPKO Pharmaceuticals, LLC | 4 | $66 |
| AstraZeneca Pharmaceuticals LP | 4 | $65 |
| Travere Therapeutics, Inc. | 2 | $49 |
| Medtronic, Inc. | 1 | $48 |
| Novo Nordisk Inc | 2 | $44 |
Products named: Fabhalta, Veltassa, XPHOZAH 30 MG, TARPEYO, JYNARQUE, RAYALDEE, FARXIGA, SYMPLICITY G3.
Industry payments across AL — which companies pay providers there.
